BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//RE4CH - ECPv6.1.2.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.research-for-children.de
X-WR-CALDESC:Events for RE4CH
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T170000
DTEND;TZID=Europe/Berlin:20200407T170100
DTSTAMP:20260816T052248
CREATED:20190828T075317Z
LAST-MODIFIED:20190828T075458Z
UID:617-1586278800-1586278860@www.research-for-children.de
SUMMARY:Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data (SC1-BHC-06-2020)
DESCRIPTION:Specific Challenge: \n\n\n\nThe  availability of appropriate decision support tools for healthcare  practitioners can promote uptake of personalised medicine in health  care. There is a need to carry out research activities aiming to develop  and validate such decision tools that would integrate available and/or  emerging diagnostic means for the area concerned\, enabling increased  precision of diagnostics and clinical decision making. On-going progress  in the fields of bioinformatics and biostatistics\, advanced analytical  tools (e.g. machine learning) up to Artificial Intelligence (AI)  solutions\, should make possible the development of devices\, platforms or  novel approaches leading to highly personalised diagnosis\, based on the  integration of data available from various sources. The ultimate result  would be a detailed health status assessment from a multitude of  viewpoints\, in a systemic way and easy to use for clinical purposes\,  leading to better diagnostic accuracy\, increased effectiveness and  efficiency of treatments. Novel hardware enabling truly innovative\,  integrative diagnostic platforms can also be considered.  \n\n\n\nScope: \n\n\n\nProposals should \ndevelop tools\, platforms or services that will use information provided \nby most relevant diagnostic means for a particular area\, resulting in an\n accurate\, detailed\, structured\, systemic and prioritised assessment of \nthe health status in a patient. The proposed solutions should integrate \nvarious data sources such as medical records\, in vitro and/or in vivo\n diagnostics\, medical imaging\, -omics data\, functional tests \n(lab-on-a-chip) etc.\, while taking into account the actual needs of \nhealthcare practitioners\, and should be tested and validated in \nreal-life settings in pilot centres\, facilitating future Health \nTechnology Assessment. These tools/platforms/services should contribute \nto improving diagnosis and clinical decision\, not only integrate \nexisting data\, and should involve intelligent human-computer interface \nsolutions to facilitate its daily use in clinical practice. Any medical \ndata relevant for a particular disease (textual data\, numerical \nmeasurements\, recorded signals\, images etc.) may be considered. The aim \nis to steer the development of solutions towards concrete patient and \npublic sector needs\, having the citizen and healthcare providers at the \ncentre. Careful attention should be paid to appropriately addressing \nethical and legal concerns\, providing adequate information to health \nprofessionals and patients to support informed decisions\, and ensuring \ndata safety and privacy\, in line with existing European and \ninternational standards and legislation. Gender and sex differences \nshould be taken into consideration when relevant. \n\n\n\nThe Commission  considers that proposals requesting a contribution from the EU of  between EUR 8 and 15 million would allow this specific challenge to be  addressed appropriately. Nonetheless\, this does not preclude submission  and selection of proposals requesting different amounts.  \n\n\n\nExpected Impact: \n\n\n\nIncrease  EU’s capacity to innovate in the area of medical instruments  technologies through the development of new diagnostic tools\, platforms  or services integrating various diagnostic data and providing quick\,  detailed\, accurate and highly personalised diagnostics for optimal  decision in clinical practice.Improve the quality and  sustainability of healthcare systems through quicker and more  encompassing diagnosis of medical conditions\, leading to quicker and  better clinical decisions and timely delivery of effective personalised  treatments\, with reduction of errors and delays (and costs associated to  them).Contribute to the growth of the European diagnostics sector\, in particular for SMEs.Reinforce EU’s role among world leaders in the production of medical diagnostic devices.\n\n\n\nFor more information\, please visit the European Commission website.
URL:https://www.research-for-children.de/event/digital-diagnostics-developing-tools-for-supporting-clinical-decisions-by-integrating-various-diagnostic-data-sc1-bhc-06-2020/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235959
DTSTAMP:20260816T052248
CREATED:20191210T111618Z
LAST-MODIFIED:20191210T111621Z
UID:1340-1586217600-1586303999@www.research-for-children.de
SUMMARY:Horizon 2020: Use of Real-World Data to advance research on the management of complex chronic conditions
DESCRIPTION:Specific Challenge: \n\n\n\nThe \nnumber of people with chronic illness is growing and almost half of them\n have multiple chronic conditions. Patients with complex chronic \nconditions (CCCs) have chronic multi-morbidities or chronic disease \ncomplications that require the attention of multiple health care \nproviders or facilities as well as home-based care. A patient with CCC \npresents to the health care system with unique constellation of needs\, \ndisabilities\, or functional limitations[1].  \n\n\n\nManaging\n patients with complex chronic conditions therefore needs approaches \nthat ensure multi-disciplinary\, personalised and well accepted by the \npatient ways of care and monitoring. \n\n\n\nThe controlled randomised \nclinical trials on chronic diseases provide important information that \ncan be translated in the daily clinical practice\, but they often do not \ncomprise sufficient breadth and depth commensurate to the complexity of \ndiseases\, and to the degree of personalisation of treatment needed. \n\n\n\nReal\n World Data (referring specifically to any type of data not collected in\n a randomised clinical trial) can complement these to fill the knowledge\n gap between controlled clinical trials results and clinical practice \nneeds in real environments. They can provide new insights into disease \npatterns and help improve the safety and effectiveness of health \ninterventions.  \n\n\n\nTapping into this rich resource of ‘real world  data’ issued from daily clinical practice\, either collected on a  permanent/regular basis by public bodies or through devices and mobile  applications\, \, and smartly assembled in combination with clinical  studies\, should boost both output and relevance of controlled clinical  research results. \n\n\n\nFor more information please visit the EC website: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-12-2020
URL:https://www.research-for-children.de/event/horizon-2020-use-of-real-world-data-to-advance-research-on-the-management-of-complex-chronic-conditions/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235900
DTSTAMP:20260816T052248
CREATED:20191210T111447Z
LAST-MODIFIED:20191210T111732Z
UID:1338-1586217600-1586303940@www.research-for-children.de
SUMMARY:Horizon 2020: Addressing low vaccine uptake
DESCRIPTION:Specific Challenge: \n\n\n\nVaccines\n are one of the most important medical breakthroughs in the last 100 \nyears. Every year vaccines save millions of people around the world from\n illness\, disability and death\, and they continue to be one of the most \ncost-effective ways to increase the health and wellbeing of their \ncitizens. Despite this\, vaccination uptake faces significant challenges \nacross Europe\, and these have increased in particular over the past 20 \nyears. Recent studies have shown Europe to be the world region with the \nmost negative views towards the safety and effectiveness of vaccines\, \nand the importance of childhood vaccination[1]. \n\n\n\nRecent\n figures on collected by the World Health Organization (WHO) show that \nin 2016 only one vaccine had a coverage rate of over 95% in Europe.[2] Seasonal influenza vaccination also remains significantly below the 75% coverage target for older age groups.[3] \n\n\n\nThus\,\n coverage for many vaccines is below the recommended limit. Due to the \nlow vaccine coverage rates\, several EU Member States have faced \nconsiderable outbreaks of vaccine-preventable diseases in recent years. \nFor example\, more than 14\,000 cases of measles were reported across the \nEU in 2017[4]\,\n which is more than three times the number of cases reported in 2016. \nDuring the same period 50 people in the EU died due to measles[5]. \n\n\n\nThese  figures highlight the urgent need to get to grips with vaccine uptake  issues\, whether uptake of existing or new vaccines. Research has an  essential role to play in understanding the underlying causes of poor  vaccine uptake\, including vaccine hesitancy\, and to develop strategies  and guidelines to help Member States and Associated countries increase  vaccination coverage. A detailed understanding of the obstacles to\, and  drivers of\, vaccination uptake in various settings is necessary to  provide appropriate recommendations. \n\n\n\nFor more information please visit the EC webpage: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-bhc-33-2020
URL:https://www.research-for-children.de/event/horizon-2020-addressing-low-vaccine-uptake/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235959
DTSTAMP:20260816T052248
CREATED:20191210T111317Z
LAST-MODIFIED:20191210T111319Z
UID:1336-1586217600-1586303999@www.research-for-children.de
SUMMARY:Horizon 2020: Coordinating and supporting research on the human microbiome in Europe and beyond
DESCRIPTION:Specific Challenge: \n\n\n\nIntegration\n and application of metagenomics data from the human microbiome has \nshown large potential for personalised medicine approaches\, although \ncausal relationships and confounders are still largely unknown. \nComparable information and details about microbiome composition and \nfunctionality in healthy citizen and patients are very valuable to \ncomplete the picture i.e. to better understand the healthy microbiome \nand to predict its development. \n\n\n\nThe number of European and  international projects and initiatives is increasing but their results  and data cannot be properly compared as they have different underlying  methods\, standards and operating procedures. The International Human  Microbiome Consortium (IHMC) as well as other current initiatives aim to  strengthen international cooperation\, to increase data comparability  and to agree common standards\, procedures and methods. There is a need  to avoid having the same research carried out multiple times at  different places and to better agree at European and at international  level. This collaboration should increase coherence and data  comparability to better exploit existing microbiome data and clinical  information in a standardised way. \n\n\n\n \n\n\n\nFor more information please visit the EC website: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-hco-17-2020
URL:https://www.research-for-children.de/event/horizon-2020-coordinating-and-supporting-research-on-the-human-microbiome-in-europe-and-beyond/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200218T000000
DTEND;TZID=Europe/Berlin:20200218T235900
DTSTAMP:20260816T052248
CREATED:20200113T082839Z
LAST-MODIFIED:20200113T122817Z
UID:1375-1581984000-1582070340@www.research-for-children.de
SUMMARY:EJP RD Joint Transnational Call: “Pre-clinical Research to Develop Effective Therapies for Rare Diseases”
DESCRIPTION:The ERA-Net E-Rare has successfully implemented ten Joint \nTransnational Calls for rare disease research projects since 2006. This \neffort continues in the framework of the European Joint Programme on Rare Diseases (EJP RD)\n that has been established to further help in coordinating the research \nefforts of European\, Associated and non-European countries in the field \nof rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). \n\n\n\nThe aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise\, with a clear future benefit for patients. \n\n\n\nThe deadline for registration and submission of pre-proposals is the 18th of February 2020.  \n\n\n\nResearch proposals must cover at least one of the following areas: \n\n\n\nDevelopment of novel therapies in a preclinical setting (including \nsmall molecules\, repurposing drugs\, cell and gene advanced therapies) \nfocusing on condition(s) with unmet medical needsUse of disease models suitable for medicinal product’s development according to EMA guidelinesDevelopment of predictive and pharmacodynamics (PD) biomarkers (with\n appropriate analytical methods e.g. OMICS) in a preclinical setting \n(e.g. in the validated model or in pre-collected human samples) for \nmonitoring the efficiency of the therapy. The model chosen must mimic \nthe human diseases and be transposable so that the biomarker identified \nin animals can be valid for humansProof of principle studies fostering an early (pre-clinical) stage \nof drug development (excluding interventional clinical trials of phase \n1-4).\n\n\n\nThe following approaches and topics are excluded from the scope of the call: \n\n\n\nTherapeutic approaches concerning rare infectious diseases\, rare  cancers and rare adverse drug events in treatments of common diseasesInterventional clinical trialsSurgery or radiation therapiesStudies that focus on research to accelerate diagnosis or to set up  new registry/cohort studies to explore disease progression and  mechanisms as these were the focus of JTC 2019.Rare neurodegenerative diseases which are within the main focus of the Joint Programming Initiative on Neurodegenerative Disease Research (JPND).  These are: Alzheimer’s disease and other dementias; Parkinson’s disease  (PD) and PD-related disorders; Prion disease; Motor Neuron Diseases;  Huntington’s disease; Spinal Muscular Atrophy and dominant forms of  Spinocerebellar Ataxia.  Interested researchers should refer to the  relevant JPND calls.       Childhood dementias/neurodegenerative diseases are not excluded.\n\n\n\nFor more information\, please visit the EJP RD webpage here.
URL:https://www.research-for-children.de/event/ejp-rd-joint-transnational-call-pre-clinical-research-to-develop-effective-therapies-for-rare-diseases/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200215T000000
DTEND;TZID=Europe/Berlin:20200215T235900
DTSTAMP:20260816T052248
CREATED:20191212T110123Z
LAST-MODIFIED:20191212T110125Z
UID:1349-1581724800-1581811140@www.research-for-children.de
SUMMARY:Fritz Thyssen Stiftung: Molecular causes in the development of illnesses
DESCRIPTION:I n accordance with one of the desires of the donors\, special attention is  devoted by the foundation institutions to medical research. At present  the foundation is focusing its support on the field of “Molecular causes  in the development of illnesses”.  This programme supports molecular  biological studies of illnesses whose development is based on genetic  defects or with which gene variants contribute to the development of  complex illnesses.  \n\n\n\nMore information about this research focus of the Foundation can be found here: https://www.fritz-thyssen-stiftung.de/en/funding/promotion-areas/medicine-and-natural-sciences/ \n\n\n\nMore information about submitting an application can be found here: https://www.fritz-thyssen-stiftung.de/en/funding/types-of-support/support-of-projects/
URL:https://www.research-for-children.de/event/fritz-thyssen-stiftung-molecular-causes-in-the-development-of-illnesses/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200214T000000
DTEND;TZID=Europe/Berlin:20200214T235900
DTSTAMP:20260816T052248
CREATED:20191127T110107Z
LAST-MODIFIED:20191127T110514Z
UID:1300-1581638400-1581724740@www.research-for-children.de
SUMMARY:Geschlechtsspezifische Besonderheiten bei Gesundheitsförderung und Prävention in Lebenswelten
DESCRIPTION:Wissenschaftliche Erkenntnisse \nzeigen\, dass das Geschlecht sowohl Einfluss auf den Erhalt der \nGesundheit als auch auf die Entstehung von Krankheiten hat. Dies kann zu\n ungleichen Gesundheitschancen beitragen. Bislang werden \ngeschlechtsspezifische Besonderheiten bei der Entwicklung und Umsetzung \nvon Maßnahmen der Gesundheitsförderung und Prävention noch wenig \nberücksichtigt. Ein besseres Verständnis geschlechtsspezifischer \nBesonderheiten sowie Erkenntnisse zu Ursachen und Auswirkungen sind \nhierfür erforderlich. \n\n\n\nDas GKV-Bündnis für Gesundheit fördert daher\n interdisziplinäre und praxisorientierte Forschungsvorhaben\, die \ngeschlechtsspezifische Besonderheiten untersuchen und adäquate Ansätze \nfür Maßnahmen der lebensweltbezogenen Gesundheitsförderung und \nPrävention entwickeln. \n\n\n\nDas Förderangebot richtet sich an: \n\n\n\nStaatliche und nichtstaatliche (Fach-)HochschulenUniversitäre und außeruniversitäre ForschungseinrichtungenGemeinnützige Körperschaften (z. B. eingetragene Vereine\, Stiftungen und gemeinnützige GmbHs)\n\n\n\nhttps://www.gkv-buendnis.de/forschung-im-buendnis/foerderung-forschungsvorhaben/
URL:https://www.research-for-children.de/event/geschlechtsspezifische-besonderheiten-bei-gesundheitsforderung-und-pravention-in-lebenswelten/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200204T000000
DTEND;TZID=Europe/Berlin:20200204T235900
DTSTAMP:20260816T052248
CREATED:20191212T092049Z
LAST-MODIFIED:20191212T092051Z
UID:1345-1580774400-1580860740@www.research-for-children.de
SUMMARY:ERC Consolidator Grants
DESCRIPTION:Are you a scientist who wants to consolidate your independence  by establishing a research team and continuing to develop a success  career in Europe? The ERC Consolidator Grant could be for you. You can  also apply if you have recently created an independent\, excellent  research team and want to strengthen it.  \n\n\n\nResearchers of any nationality with 7-12 years of experience since completion of PhD (Extensions are possible under certain circumstances — see the latest ERC Work Programme)\, a scientific track record showing great promise and an excellent research proposal.  \n\n\n\n\n	Consolidator Grants may be awarded up to € 2 million for a period of 5 years.\n (pro rata for projects of shorter duration). However\, an additional € 1\n million can be made available to cover eligible “start-up” costs for \nresearchers moving from a third country to the EU or an associated \ncountry and/or the purchase of major equipment and/or access to large \nfacilities and/or other major experimental and field work costs. \n\n\n\nFor more information\, please see the ERC website here: https://erc.europa.eu/funding/consolidator-grants
URL:https://www.research-for-children.de/event/erc-consolidator-grants/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200127T103000
DTEND;TZID=Europe/Berlin:20200127T120000
DTSTAMP:20260816T052248
CREATED:20200123T091618Z
LAST-MODIFIED:20200123T091620Z
UID:1452-1580121000-1580126400@www.research-for-children.de
SUMMARY:Info Event: Elite Program for Post-docs from the Baden-Württemberg Stiftung
DESCRIPTION:Das Programm richtet \nsich an herausragend qualifizierte Nachwuchswissenschaftler/-innen\, die \neine Hochschullehrerlaufbahn anstreben. \n\n\n\nDie Ausschreibung ist offen für alle Fachbereiche\, bezieht aber nicht den Bereich der klinischen Medizin\n mit ein. Im Eliteprogramm können jedoch \nlebenswissenschaftliche/medizinische Vorhaben finanziert werden\, die der\n Grundlagenforschung zuzuordnen sind. Eine klinische Tätigkeit\, in der \neine Arzt-Patient-Beziehung gegeben ist\, bleibt ausgeschlossen. \n\n\n\nAus den Anträgen muss \ndeutlich eine über dem Durchschnitt liegende Befähigung zur \nwissenschaftlichen Karriere erkennbar sein. Voraussetzung ist\, dass die \nBewerber/-innen ihr Forschungsvorhaben an einer der \npromotionsberechtigten Hochschulen des Landes durchführen wollen und \nihren Lebensmittelpunkt in Baden-Württemberg haben. \n\n\n\nDie Förderung pro \nVorhaben beträgt bis zu 150.000 € für drei Jahre die als \nInfrastrukturmittel für die Ausstattung der Postdoktorandinnen und \nPostdoktoranden gewährt werden. Infrastrukturmittel sind Personalmittel\,\n Reisemittel\, Sachmittel und Investitionsmittel. Die Stelle der \nPostdoktorandin bzw. des Postdoktoranden selbst kann nicht aus den \nMitteln des Eliteprogramms bezahlt werden. \n\n\n\nEin Eigenanteil von \nmindestens 10% muss durch die Einrichtung (Klinik\, Institut) selbst \naufgebraucht werden\, wobei die für die Antragsteller/-innen \naufgewendeten Personalmittel hierauf nicht angerechnet werden dürfen. \n\n\n\nFür Interessierte an diesem Programm findet am Montag\, den 27.01.2020\, 10.30–12 Uhr\, eine Informationsveranstaltung im Seminarraum der Freiburg Research Services (Friedrichstraße 41-43\, 2. OG\, Raum 02.003) statt. Anmeldungen werden bis zum 23.01.2020 per E-Mail an merle.ueding@frs.uni-freiburg.de erbeten. \n\n\n\nBitte informieren Sie \ndas Forschungsdekanat frühzeitig über Ihre geplante Antragstellung. Sie \nerhalten dann weitere Informationen\, welche Ihnen die Antragstellung \nerleichtern. \n\n\n\nDie Zahl der Anträge \npro Hochschule ist begrenzt. Die Universität Freiburg kann bis zu 7 \nBewerbungen einreichen. Anträge werden daher einer universitätsinternen \nKommission zur Auswahl vorgelegt\, die über die Weiterleitung der Anträge\n entscheidet. Von Wiedereinreichungen bitten wir abzusehen. \n\n\n\nBitte reichen Sie Ihren Antrag ausschließlich digital beim Forschungsdekanat (forschungsdekanat@uniklinik-freiburg.de) ein. \n\n\n\nRückfragen können Sie jederzeit gerne unter Tel.-Nr. 0761/270-72450 oder per Email (forschungsdekanat@uniklinik-freiburg.de) an Herrn Hölzl stellen. \n\n\n\nEinreichungsfrist beim Forschungsdekanat: 18.03.2020 \n\n\n\nhttp://www.med.uni-freiburg.de/de/forschung/forschungsfoerderung/national/national#elite
URL:https://www.research-for-children.de/event/info-event-elite-program-for-post-docs-from-the-baden-wurttemberg-stiftung/
CATEGORIES:Funding Deadlines
END:VEVENT
END:VCALENDAR